Day: March 12, 2026

Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

Working to advance TSC-related epilepsy program, with a focus on capital efficiency AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) — Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Net loss for 2025 was $91.0 million, or $1.88 per share, compared to a net loss of $24.3 million, or $0.53 per share (basic), in 2024. Net cash used in operations was $32.3 million...

Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026 Oversubscribed registered direct offering of over $28 million priced above marketInitial financing tranche of over $6 million, which will provide cash runway to the end of the third quarter enabling funding through potential NDA acceptance decision by the FDA Completion of this financing through its three tranches is expected to provide the Company with sufficient capital into 2027SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial...

Core AI Holdings and Optimus Tech Launch OptiCore Datacenters to Power AI Research at R1 Universities

Written by Customer Service on March 12, 2026. Posted in Public Companies.

Joint venture to deliver sovereign data center infrastructure supporting advanced AI and machine learning at elite research institutions Unlocks Strategic Market Opportunities While Supporting AI Research at America’s Leading Universities Public Private Partnerships with R1 Universities Miami, March 12, 2026 (GLOBE NEWSWIRE) — Core AI Holdings, Inc. (Nasdaq: CHAI) (“Core AI” or the “Company”), a global AI technology and infrastructure company, today announced the formation of a joint venture (JV) with Optimus Technology Group, a Texas based high performance data center developer and operator, to create OptiCore data centers. The JV will be dedicated to developing and operating sovereign AI data centers near the nation’s leading research universities. Building on Optimus’ decades of experience, OptiCore will focus on serving the...

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics’ Vivasure acquisition proceeds $33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025 Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programsNEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today reported its full year 2025 financial results and provided...

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026 Company plans to submit a Biologics License Application (BLA) for aglatimagene in localized, intermediate-to high-risk prostate cancer in Q4 2026 Company announced investigational new drug (IND) clearance for linoserpaturev (CAN-3110) in recurrent high-grade glioma (rHGG) to support enabling work for a potential future randomized controlled phase 2 dose regimen finding study. Entered into a $130 million term loan facility with Trinity Capital Inc. (Trinity Capital) with $50 million drawn down at closing, and access of up to an additional $80 million Cash and cash equivalents...

Publicis doubles down on predictive measurement with the acquisition of AdgeAI

Written by Customer Service on March 12, 2026. Posted in Public Companies.

Publicis doubles down on predictive measurement with the acquisition of AdgeAI Combined power of Adge’s proprietary measurement solutions and Publicis’ end-to-end AI production platform, removes the guesswork around creative performance and drives tangible business outcomes for brands. March 12, 2026 – Paris – Publicis Groupe [Euronext Paris FR0000130577, CAC 40] today announces the acquisition of industry-leading measurement and content intelligence company AdgeAI. A partner to some of the world’s biggest brands and platforms, Adge’s AI-powered analytics platform optimizes creative and video performance by analysing engagement and conversion data, identifying the most effective creative elements, and delivering actionable insights that guide content strategy and improve ROI across campaigns. At a time when it’s never been easier,...

BIO-key Partners with TD SYNNEX Public Sector (DLT) to Deliver Identity-Bound Biometric and IAM Solutions to the U.S. Public Sector

Written by Customer Service on March 12, 2026. Posted in Public Companies.

HOLMDEL, N.J., March 12, 2026 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions enabling phoneless, tokenless, passwordless, and phishing-resistant authentication, today announced a strategic partnership with TD SYNNEX Public Sector (DLT Solutions), a leading technology partner to the U.S. public sector, to bring BIO-key’s comprehensive suite of security solutions to federal, state, and local government agencies. DLT is a unit of TD SYNNEX (NYSE: SNX), a leading global end-to-end distributor of technology products, services and solutions. As government entities face increasing mandates to adopt Zero Trust architectures and phishing-resistant multi-factor authentication (MFA), the partnership between BIO-key and DLT provides...

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Written by Customer Service on March 12, 2026. Posted in Public Companies.

TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease). The patent publication highlights the potential of a 5-methoxy-2-aminoindane (MEAI)-Palmitoylethanolamide (PEA) combination...

Beamr to Demonstrate ML-Safe Video Data Compression for Physical AI at GTC 2026

Written by Customer Service on March 12, 2026. Posted in Public Companies.

Herzliya, Israel, March 12, 2026 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video optimization technology and solutions, today announced it will demonstrate a validated ML-safe video data compression for physical AI applications at GTC 2026. The company will showcase GPU-accelerated workflows for autonomous vehicles (AV) that reduce file sizes by up to 50% while preserving machine learning (ML) model accuracy. Physical AI applications, including AVs, robotics, and smart spaces, use petabyte-scale volumes of video data for training and validation, and volumes continue to grow rapidly. Teams managing tens or hundreds of petabytes of real-world and synthetic video data require reliable compression workflows that preserve ML accuracy in various environments, including world foundation models. However, conventional...

Sunrise Realty Trust, Inc. Announces Financial Results for the Fourth Quarter and Full Year 2025

Written by Customer Service on March 12, 2026. Posted in Earnings Releases And Operating Results.

Fourth quarter 2025 GAAP net income of $1.6 million or $0.12 per basic weighted average common share and Distributable Earnings(1) of $3.5 million or $0.27 per basic weighted average common share Full year 2025 GAAP net income of $12.1 million or $0.93 per basic weighted average common share and Distributable Earnings of $15.2 million or $1.19 per basic weighted average common share Board of Directors declares a first quarter 2026 dividend of $0.30 per common share WEST PALM BEACH, Fla., March 12, 2026 (GLOBE NEWSWIRE) — Sunrise Realty Trust, Inc. (Nasdaq: SUNS) (“SUNS” or the “Company”), a lender on the Tannenbaum Capital Group (“TCG”) Real Estate platform, today announced its results for the fourth quarter and year ended December 31, 2025. SUNS reported generally accepted accounting principles (“GAAP”) net income of $1.6 million...

Day: March 12, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals